News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No major headlines emerged in the past hour, leaving markets without fresh directional catalysts.
  • Equity trading remained muted as investors awaited new economic or corporate news.
  • Fixed-income markets showed limited movement absent fresh policy or inflation developments.
  • FX and commodity markets traded quietly with no major supply shocks or geopolitical triggers.
  • No significant central-bank comments, fiscal moves, or geopolitical events were reported this hour.
  • Overall market participants stayed on the sidelines awaiting clearer catalysts to drive risk appetite.

Latest Articles

Acuity Pullback: Buy the Intelligent Spaces Story on a Clear Risk-Reward

Acuity Pullback: Buy the Intelligent Spaces Story on a Clear Risk-Reward

Acuity Inc. (AYI) has delivered accelerating growth in its Acuity Intelligent Spaces (AIS) business and is generating strong cash flow while returning capital. The stock is trading below short-term moving averages and is showing oversold technicals, creating a favorable entry for a long trade. This idea lays out an actionable entry, stop and target…

Wyndham Hotels: Buy the Dip as Domestic RevPAR Recovery Gains Traction

Wyndham Hotels: Buy the Dip as Domestic RevPAR Recovery Gains Traction

Wyndham (WH) is trading near its 52-week low despite improving domestic RevPAR commentary in the industry and a resilient franchise model that generates free cash flow. With a $5.06B market cap, $323M in free cash flow and a $0.43 quarterly dividend, the stock offers a risk-reward that favors a tactical long entry around $68.18 for a mid-term recov…

Grifols: Plasma Margin Recovery Is the Easiest Path to a Cheap Re-rate

Grifols: Plasma Margin Recovery Is the Easiest Path to a Cheap Re-rate

Grifols is a low-multiple, cash-generative plasma therapeutics company trading at $7.40 with a market cap near $6.63B. If plasma collection and fractionation economics normalize — improving margins and easing regulatory overhangs — the equity should re-rate from its current P/B and P/E to levels more consistent with specialty peers, offering meanin…

Oil retreats as Saudi alternate shipments ease immediate supply concerns

Oil retreats as Saudi alternate shipments ease immediate supply concerns

Oil prices slipped in early trade as reports that Saudi Arabia is offering additional crude loadings via ship-to-ship transfers off Oman reduced near-term supply disruption concerns. Brent and U.S. crude extended losses after sharp declines the previous day, while underlying geopolitical tensions and weaker-than-expected U.S. inventory draws contin…

U.S. Temporarily Loosens Driving-Hour Rules for Gasoline and Diesel Truckers

U.S. Temporarily Loosens Driving-Hour Rules for Gasoline and Diesel Truckers

The U.S. Department of Transportation has issued a 90-day waiver that permits drivers carrying gasoline and diesel to be on duty up to 16 hours in any 24-hour period, up from the standard 14 hours, provided required rest breaks are taken. The Federal Motor Carrier Safety Administration said the measure is intended to provide flexibility in the face…

BCB Bancorp, Inc. Announces Pricing of Common Stock Offering

BCB Bancorp, Inc. Announces Pricing of Common Stock Offering

BCB Bancorp, the holding company for BCB Community Bank, has priced an underwritten public offering of 11 million shares of common stock, expected to raise approximately $85.25 million before expenses. The proceeds will be used for general corporate purposes including maintaining liquidity, funding working capital, supporting bank capital, managing…

Buy the Dip: Schneider National Is Set to Weather a Choppy Freight Cycle

Buy the Dip: Schneider National Is Set to Weather a Choppy Freight Cycle

Schneider National (SNDR) looks oversold after a pullback from its 52-week high. The company’s diversified business mix, healthy cash generation and modest leverage provide a cushion as freight markets wobble. This trade targets a measured rebound to $38 with a tight stop, balanced for a long-term (180 trading days) horizon and a favorable risk-rew…

Willdan Director Thomas D. Brisbin Sells $389k in Company Stock

Willdan Director Thomas D. Brisbin Sells $389k in Company Stock

Thomas D. Brisbin, a director at Willdan Group, Inc., recently sold 4,905 shares of the company’s common stock, generating aggregate proceeds of $389,254. The transactions involved the exercise of previously granted stock options followed by immediate sales. This insider activity occurs against a backdrop of robust financial performance, with Willd…

Lennar Q3 Profit Drops by More Than Half as Mortgage Rates Curb Buyer Demand

Lennar Q3 Profit Drops by More Than Half as Mortgage Rates Curb Buyer Demand

Lennar reported third-quarter profit of $283.9 million, or $1.19 per share, a decline from nearly $591 million, or $2.29 per share, a year earlier. Revenue for the quarter fell over 8% to $8.05 billion. The Miami-based builder said persistently high mortgage rates near 7%, weakening consumer confidence and higher costs are weighing on new-home dema…

Cummins: Backing the Power Play — AI Data Centers and a Truck Rebound Create a Multi-Year Growth Path

Cummins: Backing the Power Play — AI Data Centers and a Truck Rebound Create a Multi-Year Growth Path

Cummins is increasingly a 'picks-and-shovels' play on AI infrastructure while its traditional engine and components businesses show early signs of recovery. Strong Power Systems growth, healthy free cash flow, and an oversold technical setup make this a tactical long for investors looking for multi-quarter upside tied to data-center spending and a …

Why Cboe's 24/7 Push Makes it a Tactical Long

Why Cboe's 24/7 Push Makes it a Tactical Long

Cboe is positioned to win incremental trading and data dollars as more hosted products shift toward continuous hours and as institutional adoption for around‑the‑clock derivatives grows. This trade uses technical entry levels and a staged profit plan with a primary target at $95.00 over a 180 trading‑day horizon while recognizing regulatory and vol…

NextEra Still Deserves a Premium: Buy into Growth, Yield, and Scale

NextEra Still Deserves a Premium: Buy into Growth, Yield, and Scale

NextEra Energy mixes steady FPL utility cash flow, a fast-growing renewables platform, and accretive M&A optionality. At roughly $80, the stock looks like a buy for investors willing to pay a modest premium for durable cash flow, a 3% yield, and exposure to secular clean-energy demand. This trade idea lays out entry, stop, targets, catalysts and th…

Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling

Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling

Alpha Teknova, Inc. introduced the Fill-Tek Dispensing System, a proprietary technology allowing flexible filling of custom reagent orders into multiple single-use bag sizes within a single lot, eliminating previous manufacturing constraints. This innovation supports bioprocess workflows by simplifying quality control, enabling varied reagent volum…

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Inc., a clinical-stage biotech company, reported topline results from its ELPIS II Phase 2b clinical trial evaluating laromestrocel in infants with Hypoplastic Left Heart Syndrome (HLHS). The trial did not meet its primary endpoint of right ventricular ejection fraction improvement at 12 months, though laromestrocel showed a favorable sa…